Strides Arcolab has received tentative approval from US Food and Drug Administration (FDA) for one new drug application (ANDA) for fixed dose combination of Lamivudine and Zidovudine tablets 150mg/300mg under the expedited review provisions of the President's Emergency Plan for AIDS Relief (PEPFAR).
The approval will add to the overall basket of medicines available with Strides Arcolab, which also supplies ARV products to global procurement agencies.
The company has 14 manufacturing facilities across six countries and has a marketing presence in more than 60 countries in developed and emerging markets.
Shares of Strides Arcolab gained 1.48 per cent or Rs 6.40 on the Bombay Stock Exchange and were trading at Rs 438 during the morning session.
